LRPA
NBRV

L. Roy Papp & Associates’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

L. Roy Papp & Associates’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-104
Closed -$15K – 167
2020
Q1 		$15K Buy
104
+28
+37% +$8.56K ﹤0.01% 152
2019
Q4 		$25K Hold
76
– – ﹤0.01% 177
2019
Q3 		$38K Hold
76
– – 0.01% 173
2019
Q2 		$46K Buy
+76
New +$46.6K 0.01% 172

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

L. Roy Papp & Associates's NBRV Position: Q2 2020 in Review

L. Roy Papp & Associates sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2020, closing a stake of 104 shares — an estimated $15K sold.

L. Roy Papp & Associates first reported a position in NBRV in Q2 2019 and held it in 4 quarters. The position peaked at $46K in Q2 2019. 53 funds tracked by Wall St. Rank hold NBRV as of Q2 2020.

  • L. Roy Papp & Associates reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2020 after selling out during the quarter.
  • L. Roy Papp & Associates sold 104 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2020, an estimated $15K.
  • L. Roy Papp & Associates first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2019 and held it in 4 quarters.
  • L. Roy Papp & Associates's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $46K in Q2 2019.
  • 53 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2020.

Based on L. Roy Papp & Associates's 13F filing for Q2 2020, filed 11 Aug 2020.